<DOC>
	<DOCNO>NCT00523380</DOCNO>
	<brief_summary>This trial conduct Europe . The aim trial investigate efficacy rIL-21 Caelyx cancer patient relapse , persistent disease , first line therapy . Patients treat 6 month .</brief_summary>
	<brief_title>Efficacy Study Recombinant Interleukin-21 Treatment Ovarian Cancer</brief_title>
	<detailed_description />
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<criteria>Advanced epithelial Ovarian Cancer ( stage IIBIV ) Persistent progressive disease relapse within one year completion first line therapy Measurable assessable disease Eastern Cooperative Oncology Group status less equal 2 History active malignancy Signs CNS metastasis More one prior chemotherapy regimen Radiotherapy ( bone ) less 4 week prior start treatment radiotherapy ( visceral ) less 8 week First line chemotherapy complete least 1 month prior start treatment</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>